Interrupting the mechanisms of lipid uptake through the pharmacological inhibition of FATP1 with arylpiperazines (224) represents a promising therapeutic strategy for breast cancer and melanoma, as this protein is overexpressed in these tumors (175, 176). Here, SLC27A1 is linked to breast cancer.